News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: Bio-Thera Raises $241 Million In Shanghai STAR IPO For Antibody Portfolio
Bio-Thera Solutions of Guangzhou priced its IPO on Shanghai’s STAR Board to raise $241 million at a valuation of almost $2 billion. The offering, which placed 60 million shares at RMB32.76 each, was reported to be 3,225 times oversubscribed.
Read
Week In Review: AkesoBio Files For $300 Million Hong Kong IPO
AkesoBio, a Zhongshan novel drug discovery and development biopharma, filed for a $300 million Hong Kong IPO to develop its portfolio of novel mono- and bi-specific antibodies.
Read
Week In Review: Sorrento Therapeutics Fights $933 Million Take-Private Bid
Sorrento Therapeutics, a San Diego-Nanjing-Suzhou biopharma, rejected a $7 per share take-private offer from an unnamed PE company that valued the company at $933 million. Sorrento reported a loss of $57 million over the last 12 months.
Read
Week In Review: South Korea's Celltrion Plans $513 Million Biologics Facility In Wuhan
Celltrion, a South Korea biopharma, plans to build a $513 million China biologics manufacturing facility in Wuhan. The company said the plant's 120,000 liter capacity will make it the largest facility in China.
Read
Week In Review: China's I-Mab Stages $104 Million Nasdaq IPO
I-Mab, a Shanghai biotech, raised $104 million in its IPO on the Nasdaq exchange to support its portfolio of biologic products.The offering was priced at $14 per ADS but the price has moved 10% lower to $12.58 in initial trading.
Read
Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Apollomics will be responsible for developing uproleselan and GMI-1687.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications